Open for inclusion

Phase I Dose Escalating Study to Evaluate the Safety, Tolerability, Anti-Tumour Activity and Pharmacokinetic and Pharmacodynamic Profiles of Foxy-5 in Patients with Solid Cancer

Cancer type: Solide tumores

Phase: I

Principal Investigator: Mau-Sørensen Morten

Country: DK

Keywords: Denmark, Rigshospitalet, wnt5a

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02020291?term=foxy5&rank=1